Lamdong Pharmaceutical JSC 2024 AR2
The report highlights Lam Dong Pharmaceutical Joint Stock Company's (Ladophar) financial recovery and strategic restructuring in 2024, achieving a net revenue of VND 217.96 billion and returning to profitability with a pre-tax profit of VND 6.92 billion. The company expanded its domestic distribution channels, particularly through supermarkets and pharmacy chains, and advanced its international presence by obtaining Halal certification for its manufacturing plants. Ladophar also prioritized sustainable development by investing in GACP-WHO standardized artichoke and medicinal herb cultivation areas, implementing energy and water-saving measures, and actively supporting local community initiatives.
Company: Lamdong Pharmaceutical JSC
Sector: Health Care
Country: Vietnam
Year: 2024
Type: AR2
Pages: 75
Lamdong Pharmaceutical JSC
Annual Report
The report highlights Lam Dong Pharmaceutical Joint Stock Company's (Ladophar) financial recovery and strategic restructuring in 2024, achieving a net revenue of VND 217.96 billion and returning to profitability with a pre-tax profit of VND 6.92 billion. The company expanded its domestic distribution channels, particularly through supermarkets and pharmacy chains, and advanced its international presence by obtaining Halal certification for its manufacturing plants. Ladophar also prioritized sustainable development by investing in GACP-WHO standardized artichoke and medicinal herb cultivation areas, implementing energy and water-saving measures, and actively supporting local community initiatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Apr 16, 2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Employees